Ikano Therapeutics

Acquired by UCB
Developing Midazolam Nasal Spray (USL261) for acute repetitive seizures.

F-Prime Team

Sector

Life Sciences

Category

Therapeutics

Location

Montvale, NJ

Initial Investment

2006
Developing Midazolam Nasal Spray (USL261) for acute repetitive seizures.

Ikano Therapeutics is a specialty pharmaceutical company focused on developing Midazolam Nasal Spray (USL261) for acute repetitive seizures. Ikano was acquired by UCB.